What is Melanotan I?

Melanotan I (afamelanotide) is a synthetic peptide of the melanocortin group, a linear tridecapeptide and an analogue of α-MSH (α-Melanocyte-Stimulating Hormone). It has been studied in the scientific literature primarily for its potential role in stimulating melanogenesis, photoprotection and modulating skin pigmentation. The peptide acts primarily by activating the melanocortin receptor MC1R, with more limited activity towards other melanocortin receptors.

Originally developed as a research analogue of endogenous α-MSH, Melanotan I was used to study pathways involved in skin pigmentation, photoprotection mechanisms, and UV response. Interest in the peptide has subsequently expanded to include studies of its effects on oxidative stress, skin inflammation, and general phototolerance.

Observations on Melanotan I

In scientific research, Melanotan I has been studied in relation to:

• Stimulation of melanogenesis – activation of MC1R in melanocytes and increased synthesis of eumelanin

• Photoprotection – potential protective effect against UV-induced skin damage

• Improving phototolerance in models with increased sensitivity to sunlight

• Study of the effects on oxidative stress and inflammatory mediators in the skin

• Modulation of skin tone and evenness of pigmentation

Scientific data

Melanotan I has been studied in preclinical and limited clinical studies, with a specific focus on pigmentation and photoprotective effects.

• Primarily activates MC1R, leading to increased eumelanin synthesis and a darker phototype in the studied models

• Animal models describe reduced damage from UV radiation and faster skin recovery after exposure

• Skin darkening and increased photosensitivity have been reported in limited human studies.

• Its action is not associated with a significant increase in GH or IGF-1 – the effects are independent of growth hormone

• Stable pigmentation levels were observed for a period after completion of application in research settings

Dosage and administration

In the scientific literature, research dose regimens cited vary depending on the model (in vitro, animal, or human studies) and the purpose of the study. When administered subcutaneously in a research setting, doses are typically titrated gradually to assess the dynamics of pigmentation and tolerability.

At 10 mg + 3 ml bacteriostatic water:

Concentration = 3.3 mg/ml → 0.075 ml ≈ 250 μg

Example calculation values for laboratory purposes:

0.075 ml ≈ 250 μg

0.15 ml ≈ 500 μg

0.3 ml ≈ 1000 μg

The specific schemes for application in scientific settings are determined by the design of the protocol, the type of model, and the objectives of the study.

Possible side effects

In research settings, Melanotan I is generally well tolerated, but transient reactions that are dose-dependent may be observed:

• Facial flushing or feeling of warmth

• Mild nausea or temporary stomach discomfort

• Headache or feeling tired on some models

• Increased skin pigmentation and darkening of existing moles

The effects are usually reversible and resolve after discontinuation of administration in research settings. Serious adverse reactions have been rarely described within the published doses, but long-term safety and effects on skin lesions remain the subject of further studies.

The information is based on scientific publications and is purely educational in nature. It is not intended to diagnose, treat or prevent disease and does not constitute medical advice.